# COVID-19: Developing Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/covid-19-developing-drugs-and-biological-products-for-treatment-or-prevention-guidance-for-industry/a6c3249b-9395-4d0b-96dd-986a992b4139

> FDA guidance document: COVID-19: Developing Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry. Issue date: November 24, 2023. Get complete insights and analysis.

---

## Details

- Title: COVID-19: Developing Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-11-24
- Last Changed: 2025-05-02
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2020-D-1370">FDA-2020-D-1370</a>

## Related Documents

- [Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment :  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/assessing-covid-19-related-symptoms-in-outpatient-adult-and-adolescent-subjects-in-clinical-trials-of-drugs-and-biological-products-for-covid-19-prevention-or-treatment-guidance-for-industry/3993ff56-2b20-4679-8303-9876c6800402)
- [Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4  Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/certain-ophthalmic-products-policy-regarding-compliance-with-21-cfr-part-4-guidance-for-industry-guidance-for-industry/8a04c815-2f7f-4f7e-908b-6a62504eb3e4)
- [Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization](https://www.globalkeysolutions.net/guidances/guidance-document/development-of-monoclonal-antibody-products-targeting-sars-cov-2-for-emergency-use-authorization/0146d188-0350-4f83-b103-4193b8be1e41)